Adaptimmune Therapeutics (ADAP) - Net assets

Net assets on the balance sheet as of June 2025 : -£53.32 Million

According to Adaptimmune Therapeutics's latest financial reports the company has -£53.32 Million in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.

Adaptimmune Therapeutics - Net assets on balance sheet (from 2014 to 2025)

Net assets by year

Year	Net assets	Change
2024-12-31	$£9.44 M	-69.56%
2023-12-31	$£31.01 M	-54.17%
2022-12-31	$£67.67 M	-55.64%
2021-12-31	$£0.15 B	-39.05%
2020-12-31	$£0.25 B	165.51%
2019-12-31	$£94.28 M	-51.52%
2018-12-31	$£0.19 B	29.5%
2017-12-31	$£0.15 B	11.54%
2016-12-31	$£0.13 B
2015-06-30	$£0.16 B	11621.82%
2014-06-30	$£1.4 M	-199.35%
2013-06-30	$-£1.42 Million	1670.12%
2012-06-30	$-£0.09 Million

Net assets for similar companies or competitors

Company	Net assets	differencediff.	Country
Novavax NVAX	-£0.12 Billion	120.80%	🇺🇸 USA
Enzo Biochem ENZB	£32.61 M	-161.16%	🇺🇸 USA
uniQure QURE	£0.17 B	-422.37%	🇳🇱 Netherlands
Exelixis EXEL	£1.62 B	-3,145.04%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions